Clinical Trial Update: A Pilot Study of Perioperative Nivolumab and Paricalcitol to Target the Microenvironment in Resectable Pancreatic Cancer [EARLY_Phase 1]

View source ↗

Summary

Early-phase pilot study investigating perioperative nivolumab and paricalcitol to modulate the tumor microenvironment in resectable pancreatic cancer; study ter…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer

Drugs mentioned

• Paricalcitol (paricalcitol)
• nivolumab (nivolumab)

Snippet

Sponsor: Abramson Cancer Center at Penn Medicine | Conditions: Pancreatic Cancer | EARLY_Phase 1 | Status: TERMINATED | Results posted: 2024-03-15